Gene-Editing Stocks Gain After Doctor Claims Success in Babies
This article is for subscribers only.
Gene-editing stocks traded higher after a Chinese researcher claimed to have produced the world’s first genetically edited babies.
The trio of public companies developing therapies using the technology known as Crispr, the method He Jiankui claimed to use in China, outperformed peers Monday as the broader biotech market rebounded. Crispr Therapeutics AG rallied 4.5 percent, while Editas Medicine Inc. rose 3 percent and Intellia Therapeutics Inc. gained 5.5 percent. Sangamo Therapeutics In., a firm that uses a gene-editing platform known as Zinc finger nuclease, rose as much as 3.4 percent.